Navigation Links
DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth

NEW YORK, June 7, 2011 /PRNewswire/ -- DuPont (NYSE: DD) Chair and CEO Ellen Kullman told investors at the JPMorgan Diversified Industries Conference to expect attractive long-term growth from DuPont through product and process innovation, selective investment in attractive areas, broad-based growth, especially in developing markets, and a relentless focus on productivity.  Kullman also reaffirmed DuPont's 2011 earnings per share (EPS) outlook in the range of $3.65 to $3.85 per share, excluding the impact of Danisco.  As previously announced, the Danisco acquisition could reduce 2011 earnings by $.30-$.45 per share on a reported basis.

"We believe DuPont is uniquely positioned to tackle big global challenges that offer the opportunity for significant top-line growth and value creation," said Kullman.  "The recent acquisition of Danisco is a perfect fit with our growth strategy around feeding a growing population, decreasing dependence on fossil fuels and protecting people and the environment.  

"We will leverage Danisco's world-leading capabilities in enzymes and fermentation, with DuPont's strengths in biomass processing and microbial engineering.  This combination results in a powerful, integrated set of tools to create the next generation of cost-effective biofuels and biobased materials," said Kullman. "Simply put, our vision is to start with renewable raw materials and create differentiated products with excellent environmental profiles and superior economics for our customers."

Kullman indicated that DuPont continues to focus on market-driven science to meet market needs.  In 2010, 31 percent of the company's sales came from products that were introduced within the past 4 years, "We have made innovation and productivity a part of our DNA at DuPont," Kullman said.  "We are currently in the midst of a $1 billion initiative both in fixed cost productivity and working capital productivity.  We are well on our way to delivering our 2011 targets of $300 million for each.

"Our businesses are delivering strong results, building on the momentum from 2010 and first quarter 2011," said Kullman.  "We expect our resource investments, coupled with innovative product offerings and market demands aligned with the megatrends, will enrich the company's mix of high-growth, high-value offerings.  Based on current expectations for long-term sales growth, the high-growth business segments will shift from 48 percent of the portfolio in 2010 to 57 percent by 2015."

DuPont ( is a science-based products and services company.  Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere.  Operating in more than 90 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

Forward-Looking Statements:  This news release contains forward-looking statements based on management's current expectations, estimates and projections.  All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements.  Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions.  These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions.  Many factors, including those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by DuPont, particularly its latest annual report on Form 10-K and quarterly report on Form 10-Q, as well as others, could cause results to differ materially from those stated.  These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw materials, research and development of new products, including regulatory approval and market acceptance; seasonality of sales of agricultural products; and severe weather events that cause business interruptions, including plant and power outages, or disruptions in supplier and customer operations. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
2. Robert L. Brent, MD, PhD, Honored with 2008 Alfred I. duPont Award for Excellence in Childrens Health Care
3. DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels
4. DuPont and State of Delaware Unveil $80 Million Innovation Center Partnership
5. DuPont Expands Seed Production Capacity to Meet Growing Demand for Seed, Grain
6. DuPont Opens Research & Development Center in India
7. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
8. DuPont Launches Innovative Renewably Sourced Material for Carpet Cushion
9. DuPont Takes Aggressive Actions to Strengthen Competitiveness and Increase Cash Flow
10. DuPont Unveils New Strategy to Expand its Seed Business
11. DuPont Acquires Ag Data Management Business to Enhance Information Solutions for Growers
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th ... Paris from 17 th until 19 th ... leader, has invented the first combined scanner in the world ... scanning surface. Until now two different scanners were required: one ... both on the same surface. This innovation is an ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
(Date:11/11/2015)... MINNETONKA, Minn. , Nov. 11, 2015   MedNet ... the entire spectrum of clinical research, is pleased to announce ... Partnerships in Clinical Trials (PCT) event, to be held ... will be able to view live demonstrations of ... platform, and learn how iMedNet has been able ...
Breaking Biology News(10 mins):